Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockView Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q3 FY26
Discovery themes featuring this stockCorona Remedies Ltd (CORONA) is currently trading at 2,216.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
CORONA Remedies Limited is an India‑focused, branded pharmaceutical company that develops, manufactures and markets formulations across women’s healthcare, cardio‑diabeto, pain management, urology and other therapies, operating manufacturing plants in Solan (Himachal Pradesh) and Bhayla/Ahmedabad (Gujarat) with DSIR R&D and multiple GMP certifications supporting domestic and export ambitions. Financial momentum is healthy: Q3 FY26 revenue of INR 342 crore (+15% YoY) and 9M FY26 revenue of INR 1,050 crore (+16.3%), with EBITDA margins improving to 24.3% in Q3 and 22.0% for 9M, and adjusted PAT up 23.7% in Q3 and 30.7% for 9M, reflecting operating leverage and strong brand economics. Export runway expanded materially after EAEU‑GMP accreditation for the Gujarat plant, enabling access to five Eurasian markets (Russia, Kyrgyzstan, Armenia, Belarus, Kazakhstan) and a stated addressable pharmaceutical market opportunity of up to approximately USD 25 billion, positioning CORONA Remedies for measured B2B export growth over the next few years. Brand and go‑to‑market strategy is a core strength: 27 ‘engine’ brands contributed ~72% of domestic sales historically, the company has scaled acquired brands from major multinationals and plans to commercialize the Bayer portfolio including IVF and antiplatelet franchises, supported by ~600 new medical representatives added over recent years. Strong cash generation underpins growth and returns: OCF/EBITDA of 86.3% and annualised ROCE of 48.0% (9M FY26) demonstrate disciplined working‑capital and capital allocation, enabling reinvestment into product launches, modest capacity additions and selective inorganic opportunities without immediate dependence on external funding.
Over the past 52 weeks, Corona Remedies Ltd has traded between a low of ₹1,336.95 and a high of ₹2,261.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Corona Remedies Ltd has a market capitalization of approximately 13,677.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Corona Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.72 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13,677.23 Cr, Corona Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Corona Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Corona Remedies Ltd is 68.72. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board is scheduled to meet on July 31, 2026 to approve the unaudited financial results for Q1 FY27 (quarter ended June 30, 2026).
The filing states India business revenue grew 17.18% in FY 2025-26 versus IPM growth of 8.59%.
Q3 FY26 revenue from operations was INR 342.42 crore (+15% YoY) and adjusted PAT was INR 55.56 crore (+23.7% YoY), excluding a one-time statutory impact.
Bearish
6
Neutral
6
Bullish
2
Bearish
7
Neutral
10
Bullish
29
Bearish
1
Neutral
4
Bullish
27
Bearish
6
Neutral
6
Bullish
2
Bearish
6
Neutral
6
Bullish
2
Bearish
1
Neutral
4
Bullish
27
Bearish
1
Neutral
4
Bullish
27
Bearish
1
Neutral
4
Bullish
27
CORONA Remedies Limited is an India‑focused, branded pharmaceutical company that develops, manufactures and markets formulations across women’s healthcare, cardio‑diabeto, pain management, urology and other therapies, operating manufacturing plants in Solan (Himachal Pradesh) and Bhayla/Ahmedabad (Gujarat) with DSIR R&D and multiple GMP certifications supporting domestic and export ambitions.
Financial momentum is healthy: Q3 FY26 revenue of INR 342 crore (+15% YoY) and 9M FY26 revenue of INR 1,050 crore (+16.3%), with EBITDA margins improving to 24.3% in Q3 and 22.0% for 9M, and adjusted PAT up 23.7% in Q3 and 30.7% for 9M, reflecting operating leverage and strong brand economics.
Export runway expanded materially after EAEU‑GMP accreditation for the Gujarat plant, enabling access to five Eurasian markets (Russia, Kyrgyzstan, Armenia, Belarus, Kazakhstan) and a stated addressable pharmaceutical market opportunity of up to approximately USD 25 billion, positioning CORONA Remedies for measured B2B export growth over the next few years.
Brand and go‑to‑market strategy is a core strength: 27 ‘engine’ brands contributed ~72% of domestic sales historically, the company has scaled acquired brands from major multinationals and plans to commercialize the Bayer portfolio including IVF and antiplatelet franchises, supported by ~600 new medical representatives added over recent years.
Strong cash generation underpins growth and returns: OCF/EBITDA of 86.3% and annualised ROCE of 48.0% (9M FY26) demonstrate disciplined working‑capital and capital allocation, enabling reinvestment into product launches, modest capacity additions and selective inorganic opportunities without immediate dependence on external funding.
Pharmaceuticals & Biotechnology
Pharmaceuticals
13,557 Cr
Low Risk
68.1
37.4
2.1
18.3
2,261.40
1,336.95
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
810.50 | 15,964 Cr | 23.15 | 2.81 | 1.48 | 11.89 | 10.81 | 7.87 | ||
1510.00 | 15,762 Cr | 57.76 | 7.81 | 0.50 | 12.94 | 17.08 | 12.21 | ||
329.00 | 14,877 Cr | 28.54 | 4.92 | 0.27 | 13.82 | 17.37 | 13.50 | ||
819.00 | 14,599 Cr | 14.40 | 1.58 | 0.61 | 15.38 | 15.37 | 9.16 | ||
2230.60 | 13,677 Cr | 68.72 | 18.31 | 0.45 | 24.79 | 27.13 | 16.52 | ||
1211.05 | 13,561 Cr | 73.86 | 15.35 | 0.00 | 19.57 | 22.16 | 15.63 | ||
776.20 | 12,217 Cr | 41.74 | 3.69 | 0.38 | 7.70 | 10.95 | 5.37 | ||
| Median: 7 Co. | — | 819.00 | 14,599 Cr | 41.74 | 4.92 | 0.45 | 13.82 | 17.08 | 12.21 |
